Scientists uncover surprising immune response that helps tumors grow, revealing new strategies to improve treatment ...

Background: Peptide receptor radionuclide therapy (PRRT) is one of the standard treatments for unresectable or metastatic neuroendocrine tumors (NETs). Treatment with Lu177-Dotatate PRRT therapy ...

After four cycles of peptide receptor radionuclide therapy (PRRT), a complete remission according to the Response Assessment in Neuro-Oncology as well as PET criteria was recorded (right).

Peptide Receptor Radionuclide Therapy (PRRT) Market The peptide receptor radionuclide therapy (PRRT) market is projected to be valued at approximately USD 591.83 million in 2023 and is expected to ...

Because of changes in the treatment landscape and approval of peptide receptor radionuclide therapy with Lu-177 dotatate, a protocol amendment in November 2020 expanded eligibility related to ...

AlphaMedix is a targeted alpha therapy comprised of 212Pb attached to a peptide complex that targets somatostatin. Under Houston-based RadioMedix, AlphaMedix has reached Phase 2 testing.

Lu-177 dotatate is a molecular therapy. It is a type of peptide receptor radionuclide therapy (PRRT) used mainly for neuroendocrine tumors (NETs). PRRT combines a compound called a peptide with a ...

ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues R Hicks and others Neuroendocrinology, ...

212 PB-DOTAMTATE (AlphaMedixTM) received breakthrough therapy designation from the FDA, signifying the drug's potential to significantly improve over existing treatments for inoperable or metastatic, ...

The Global Peptide Receptor Radionuclide Therapy (PRRT) Industry is on the cusp of substantial growth, with a projected value of US$ 591.83 million in 2023. According to the latest market analysis, ...